SEC Form 4
Clover Health Investments, Corp (CLOV) insider trading
In the 12 months to Oct 23, 2026, 6 CLOV insiders reported open-market sales of $3.9M across 20 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $3.9M
- 20 filings · 6 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 16 of 20
- $2.9M of $3.9M sold (73%)
Who traded CLOV, and when
- Sale
- Sale, pre-arranged (10b5-1)
CLOV daily close from Oct 23, 2025 to Oct 23, 2026, between $1.70 and $5.41, last $4.60. 20 sale and 0 purchase filings by 6 insiders, marked at their filing dates. Conrad Wai, CEO, Counterpart Health: sold $2.3M across 2 filings, first filed May 28, 2026, last Sep 16, 2026. Brady Patrick Priest, CEO of Home Care → CEO of Clover Care Services: sold $724.8K across 2 filings, first filed Mar 5, 2026, last May 13, 2026. Karen Soares, Chief Legal Officer: sold $323.0K across 2 filings, first filed Jul 20, 2026, last Oct 20, 2026. Jamie L. Reynoso, CEO, Medicare Advantage: sold $266.0K across 12 filings, first filed Nov 5, 2025, last Oct 20, 2026. Carladenise Armbrister Edwards, Director: sold $229.7K across 1 filing, first filed May 19, 2026, last May 19, 2026. Joseph Frank Oldakowski, VP OF FINANCE AND CONTROLLER: sold $103.2K across 1 filing, first filed Sep 14, 2026, last Sep 14, 2026.
Largest mark · tap a row for others
Conrad Wai · CEO, Counterpart Health
Sale $1,416,000
300,000 shares at $4.72 avg
Filed Sep 16, 2026 · traded Sep 15
Pre-arranged (10b5-1) · close on filing date $4.56
Conrad Wai · CEO, Counterpart Health
CEO, Counterpart Health
$2.3M soldBrady Patrick Priest · CEO of Home Care → CEO of Clover Care Services
CEO of Home Care → CEO of Clover Care Services
$724.8K soldKaren Soares · Chief Legal Officer
Chief Legal Officer
$323.0K soldJamie L. Reynoso · CEO, Medicare Advantage
CEO, Medicare Advantage
$266.0K soldCarladenise Armbrister Edwards · Director
Director
$229.7K soldJoseph Frank Oldakowski · VP OF FINANCE AND CONTROLLER
VP OF FINANCE AND CONTROLLER
$103.2K soldHas Clover Health Investments, Corp's CEO sold stock?
Yes. Jamie L. Reynoso (CEO) sold 72,695 shares ($266.0K) between Nov 2025 and Oct 2026, all under a pre-arranged 10b5-1 plan. Conrad Wai (CEO) sold 520,426 shares ($2.3M) between May 2026 and Sep 2026, all under a pre-arranged 10b5-1 plan. Brady Patrick Priest (CEO) sold 273,039 shares ($724.8K) between Mar 2026 and May 2026. Andrew Toy (CEO) made no open-market sales filed as CEO in the last 12 months.
Open-market trades
20 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Conrad Wai | CEO, Counterpart Health | $2.3M | — | 2 | 100% of sales | |
| Brady Patrick Priest | CEO of Home Care → CEO of Clover Care Services | $724.8K | — | 2 | — | |
| Karen Soares | Chief Legal Officer | $323.0K | — | 2 | 100% of sales | |
| Jamie L. Reynoso | CEO, Medicare Advantage | $266.0K | — | 12 | 100% of sales | |
| Carladenise Armbrister Edwards | Director | $229.7K | — | 1 | — | |
| Joseph Frank Oldakowski | VP OF FINANCE AND CONTROLLER | $103.2K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Jamie L. Reynoso CEO, Medicare Advantage | SalePre-arranged (10b5-1) | 4,066 | $4.41 | $17.9K | 2,770,351 | |
traded | Karen Soares Chief Legal Officer | SalePre-arranged (10b5-1) | 19,275 | $4.66 | $89.8K | 1,573,423 | |
traded | Jamie L. Reynoso CEO, Medicare Advantage | SalePre-arranged (10b5-1) | 2,006 | $4.63 | $9.3K | 2,792,690 | |
traded | Jamie L. Reynoso CEO, Medicare Advantage | SalePre-arranged (10b5-1) | 1,921 | $4.56 | $8.8K | 2,803,446 | |
traded | Conrad Wai CEO, Counterpart Health | SalePre-arranged (10b5-1) | 300,000 | $4.72 | $1.4M | 1,170,056 | |
traded | Joseph Frank Oldakowski VP OF FINANCE AND CONTROLLER | Sale | 20,000 | $5.16 | $103.2K | 279,067 | |
traded | Karen Soares Chief Legal Officer | SalePre-arranged (10b5-1) | 51,700 | $4.51 | $233.2K | 1,505,522 | |
traded | Jamie L. Reynoso CEO, Medicare Advantage | SalePre-arranged (10b5-1) | 4,839 | $4.53 | $21.9K | 2,814,640 | |
traded | Jamie L. Reynoso CEO, Medicare Advantage | SalePre-arranged (10b5-1) | 2,384 | $4.68 | $11.2K | 2,832,598 | |
traded | Jamie L. Reynoso CEO, Medicare Advantage | SalePre-arranged (10b5-1) | 2,360 | $4.78 | $11.3K | 2,841,211 | |
traded | Jamie L. Reynoso CEO, Medicare Advantage | SalePre-arranged (10b5-1) | 7,289 | $4.91 | $35.8K | 2,849,921 | |
traded | Conrad Wai CEO, Counterpart Health | SalePre-arranged (10b5-1) | 220,426 | $3.99 | $879.5K | 1,390,056 | |
traded | Carladenise Armbrister Edwards Director | Sale | 67,160 | $3.42 | $229.7K | 285,432 | |
traded | Brady Patrick Priest CEO of Clover Care Services | Sale | 98,039 | $3.52 | $345.1K | 2,040,222 | |
traded | Jamie L. Reynoso CEO, Medicare Advantage | SalePre-arranged (10b5-1) | 5,833 | $1.91 | $11.1K | 2,716,735 | |
traded | Brady Patrick Priest CEO of Home Care | Sale | 175,000 | $2.17 | $379.8K | 1,998,584 | |
traded | Jamie L. Reynoso CEO, Medicare Advantage | SalePre-arranged (10b5-1) | 4,597 | $2.58 | $11.9K | 2,737,700 | |
traded | Jamie L. Reynoso CEO, Medicare Advantage | SalePre-arranged (10b5-1) | 2,102 | $2.53 | $5.3K | 2,757,029 | |
traded | Jamie L. Reynoso CEO, Medicare Advantage | SalePre-arranged (10b5-1) | 4,913 | $2.61 | $12.8K | 2,767,240 | |
traded | Jamie L. Reynoso CEO, Medicare Advantage | SalePre-arranged (10b5-1) | 30,385 | $3.58 | $108.8K | 2,793,411 |
GET /stocks/filings/vX/form-4?tickers=CLOV&filing_date.gte=2025-10-23&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"CLOV"
],
"issuer_cik": "0001801170",
"owner_cik": "0001999086",
"accession_number": "0001999086-26-000034",
"form_type": "4",
"filing_date": "2026-10-20",
"period_of_report": "2026-10-20",
"issuer_name": "CLOVER HEALTH INVESTMENTS, CORP. /DE",
"issuer_trading_symbol": "CLOV",
"owner_name": "Soares Karen",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Legal Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-20",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 19275,
"transaction_price_per_share": 4.66,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 1573423,
"transaction_value": 89821.5,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported in this Form 4 were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 13, 2026."
},
{
"id": "F2",
"description": "The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.45 to $4.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."
}
]
},
{
"tickers": [
"CLOV"
],
"issuer_cik": "0001801170",
"owner_cik": "0001839066",
"accession_number": "0001839066-26-000057",
"form_type": "4",
"filing_date": "2026-10-20",
"period_of_report": "2026-10-19",
"issuer_name": "CLOVER HEALTH INVESTMENTS, CORP. /DE",
"issuer_trading_symbol": "CLOV",
"owner_name": "Reynoso Jamie L.",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "CEO, Medicare Advantage",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-19",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 4066,
"transaction_price_per_share": 4.41,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 2770351,
"transaction_value": 17931.06,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026."
},
{
"id": "F2",
"description": "The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.32 to $4.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 79 records
- Option exercises1 record
- Tax withholding42 records
- Tax withholding (sold to cover)22 records
- Grants and awards14 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for CLOV every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.